| P50 | author | Gerald Brandacher | Q64124356 |
| P2093 | author name string | Robert A Montgomery | |
| | Zhaoli Sun | |
| | W P Andrew Lee | |
| | Angelo A Leto Barone | |
| P2860 | cites work | The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 |
| | Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 |
| | Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 |
| | Alemtuzumab (Campath-1H): a systematic review in organ transplantation | Q36491577 |
| | Vascular remodeling in transplant vasculopathy | Q36790459 |
| | 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation | Q36795985 |
| | Banff 2011 Meeting report: new concepts in antibody-mediated rejection | Q37058043 |
| | The Banff 2007 working classification of skin-containing composite tissue allograft pathology. | Q37150363 |
| | Defining unacceptable HLA antigens | Q37236970 |
| | Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection | Q37654098 |
| | Humoral immunity and antibody-mediated rejection in solid organ transplantation. | Q37940722 |
| | Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale | Q37990988 |
| | Phenotypes of antibody-mediated rejection in organ transplants | Q38005448 |
| | Prevention of antibody-mediated kidney transplant rejection | Q38010231 |
| | A GPS for finding the route to transplantation for the sensitized patient | Q38019742 |
| | Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts | Q39477756 |
| | Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Laryngeal transplantation: research, clinical experience, and future goals | Q40159228 |
| | Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 |
| | A Critical Appraisal of Methods to Grade Transplant Glomerulitis in Renal Allograft Biopsies | Q42846833 |
| | Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation | Q42872851 |
| | Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access | Q42968367 |
| | Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection | Q43166691 |
| | The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients | Q43856835 |
| | Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure | Q43918875 |
| | Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis | Q44228631 |
| | Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab | Q44584381 |
| | Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates | Q45178439 |
| | Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: I. Evaluation of the GTI QuikID assay and analysis of antibody patterns | Q47634524 |
| | Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 |
| | Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 |
| | Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. | Q51413561 |
| | CD3+-mediated rejection and C4d deposition in two composite tissue (bilateral hand) allograft recipients after induction with alemtuzumab. | Q51762959 |
| | A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. | Q53639822 |
| | Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. | Q53890647 |
| | "Hyperacute" renal-homograft rejection in man. | Q54626072 |
| | Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 |
| P433 | issue | 9 | |
| P304 | page(s) | 835-844 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Impact of donor-specific antibodies in reconstructive transplantation | |
| P478 | volume | 9 | |